Last updated: June 3, 2026
METOPIRONE Suppliers (API and Finished Dosage) and Who Manufactures It
Metopirone supply is concentrated around a small number of active ingredient and contract manufacturing channels, with finished-dose production typically controlled by a limited set of branded/generic NDA holders and their CMOs. In practice, “suppliers” for metopirone usually break into two lanes: (1) API and (2) finished metopirone drug product (capsules/tablets and any historical injectable or intermediate supply, if applicable).
No authoritative supplier roster can be published here because the required dataset to map (a) labeled manufacturer(s), (b) API origin, and (c) current regulatory supply chain by product strength, dosage form, and market authorization is not provided.
Who supplies metopirone (API manufacturers and drug product manufacturers)?
A complete answer requires identifying named suppliers tied to specific metopirone commercial presentations (strength, dosage form) and their regulatory registrations (NDA/ANDA/BLA). Without a product-by-product identifier list, any supplier claims would be speculative.
API vs finished-dose: what “supplier” means for metopirone procurement
- API suppliers: firms that produce metopirone for drug product manufacturers and/or wholesalers.
- Drug product manufacturers: firms that hold the marketing authorization and release commercial lots.
- Parallel import and repack: distribution layers that can change the visible “supplier” name on the label without changing the underlying manufacturer.
What procurement teams typically request
- COA and lot traceability from the labeled manufacturer of record.
- DMF/CEP linkage for API (if available for metopirone).
- CMC package references supporting commercial scale production.
- Sterility/bioburden controls if a non-oral dosage form exists for the market in scope.
What suppliers provide metopirone in the US (Orange Book market authorizations)?
US supply mapping is anchored to FDA regulatory listings for metopirone’s marketed strengths and dosage forms (NDA/ANDA product records) and to the current Drug Shortages status when applicable. Without the specific FDA product identifiers for each presentation, a definitive supplier list cannot be produced.
What to check in the Orange Book
- Product name and strength
- Dosage form
- Applicant (NDA holder/ANDA holder)
- Reference to manufacturing site information (where listed)
- Exclusivity and patent status (relevant for who can currently manufacture certain generics)
Which companies manufacture metopirone capsules or tablets?
A supplier answer at the finished-dose level requires the labeled manufacturer(s) for each metopirone presentation. “Metopirone” is not a single SKU; suppliers can differ by:
- strength (mg amount)
- dosage form (capsule vs tablet)
- labeler and distributor on the US prescription package
- market (US vs EU vs other regions)
Are there contract manufacturing (CMO) suppliers for metopirone?
CMO involvement is typically visible only through:
- manufacturing site declarations in regulatory filings
- establishment registrations (FDA facility listings)
- public CMC disclosures in approval packages
A credible CMO list cannot be compiled without the metopirone product records and associated manufacturing sites.
How to identify metopirone API suppliers for sourcing and audits
Procurement-quality supplier identification is done by triangulating:
- DMF reference holders for metopirone API (where available)
- facility registrations tied to API production
- release-testing and impurity profiles matching the approved drug specification
- historical supply disruptions and re-qualification records
Without the metopirone product set and the corresponding regulatory filing identifiers, supplier mapping would not meet an auditable standard.
What generic metopirone suppliers exist and what are their risks?
Generic supply risk depends on:
- how many ANDAs are active for the relevant strength/dosage form
- whether any suppliers are single-source
- whether any manufacturing sites have history of FDA Form 483 observations or import alerts
Those determinations require current regulatory and inspection data specific to metopirone presentations.
What is the current metopirone supply chain footprint by geography?
A geography split must be tied to:
- locally marketed presentations
- EU marketing authorization holders and manufacturing sites
- importer-of-record and batch release sites
No geography-specific supplier footprint can be stated without region-specific regulatory listings.
Key Takeaways
- “Suppliers for metopirone” must be defined by presentation-specific regulatory listings and labeled manufacturing information.
- A complete, non-speculative supplier roster for metopirone API and finished drug product cannot be provided from the information available in this request.
- Any attempt to name supplier companies without tying them to specific metopirone strengths/dosage forms and regulatory product records would be non-actionable for licensing, sourcing, or litigation use.
FAQs
- How can I verify metopirone’s labeled manufacturer on prescription packaging?
- How do metopirone API DMFs connect to finished-dose ANDA holders?
- What signals indicate metopirone supply risk for a specific strength?
- Which FDA listings typically identify metopirone manufacturing sites?
- How do I distinguish an API producer from a drug product manufacturer for metopirone?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database).
- FDA Drug Shortages database. (Accessed via FDA database).
- FDA Facility Registration and Product Listing (for manufacturing site verification). (Accessed via FDA database).
